Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026
INTEGRATED BIOPHARMA INC (INBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE for September 25, 2026 Contact: Dina Masi, CFO Integrated BioPharma, Inc. investors@ibiopharma.com 888.319.6962 Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026 HILLSIDE, NEW JERSEY (September 25, 2026) - Integrate
How this was made
The 30-second read
Why it matters
The earnings miss and loss reversal suggest near‑term pressure on the stock, though the company may benefit from its niche contract‑manufacturing position if it diversifies its customer base.
Market read
Micro‑cap earnings release with a significant revenue decline; likely to move INBP but limited broader market effect.
What to watch
Potential upside from upcoming regulatory approvals or new product launches not disclosed yet.
Background
Integrated BioPharma (OTCQX:INBP) filed an 8‑K reporting its Q2 and FY 2026 results.
Ticker impact
Integrated BioPharma disclosed a 31% quarterly revenue decline and a fiscal‑year operating loss in its 8‑K filing.
Potential short‑term downside pressure pending market reaction.
The company reported lower revenue and a swing to loss versus prior profit, which typically triggers sell‑side activity for micro‑caps.
Market effects
Highlights weakness in contract‑manufacturing segment of nutraceuticals.
Limited to US OTC market; minimal broader impact.
Low; micro‑cap earnings do not affect major indices.
Counterpoint
If the company can secure new contracts, the price dip may present a buying opportunity.
Key entities
- companyIntegrated BioPharma Inc.
OTCQX‑listed contract manufacturer of vitamins and nutraceuticals.
- executiveRiva Sheppard
Co‑Chief Executive Officer of Integrated BioPharma.
- executiveChristina Kay
Co‑Chief Executive Officer of Integrated BioPharma.
